RXRX
Recursion Pharmaceuticals Inc
3.90$
+5.1%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Cash Flow
Recursion Pharmaceuticals Inc (RXRX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -106 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18 | -17 | -19 | 8.6 | -31 | -34 | -33 | -61 | 77 | -62 | -55 | -45 | -73 | -67 | -73 | -74 | -102 | -82 | -59 | -115 | -132 | -76 | -117 | -46 | -81 | -106 | -350 | |
| 0.9 | 1.0 | 0.9 | 1.6 | 1.4 | 2.3 | 2.4 | 2.2 | 2.8 | 2.8 | 3.0 | 3.2 | 3.7 | 5.5 | 7.6 | 7.6 | 7.4 | 9.0 | 7.2 | 13 | 19 | 24 | 21 | 19 | 20 | 18 | 78 | |
| 1.3 | 0.8 | 1.1 | 1.2 | 1.8 | 5.3 | 3.4 | 4.3 | 5.6 | 5.7 | 8.9 | 7.7 | 8.8 | 12 | 17 | 16 | 16 | 17 | 18 | 31 | 36 | 26 | 25 | 24 | 22 | 19 | 91 | |
| 1.3 | 0.6 | 3.3 | – | 1.9 | 7.7 | 4.7 | 5.5 | 6.0 | 8.7 | 8.7 | 10 | 11 | 12 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -1.6 | 0.6 | 0.3 | 32 | -4.6 | 1.0 | 7.3 | -4.0 | 123 | -9.5 | -7.8 | -0.6 | -24 | -10 | -4.5 | -11 | -36 | -7.3 | -0.3 | 6.0 | -5.9 | 35 | -26 | 11 | -7.8 | -19 | -42 | |
| 0.7 | 0.6 | 0.8 | 4.6 | 19 | 6.2 | 9.7 | 4.5 | 4.3 | 16 | 8.6 | 8.0 | 5.3 | 4.0 | 0.8 | 2.4 | 6.7 | 4.2 | 4.6 | 1.6 | 1.8 | 3.2 | 0.2 | 1.2 | 0.3 | 2.0 | 3.8 | |
| -0.7 | 0.0 | -3.4 | -4.6 | -19 | -6.2 | -194 | -52 | 143 | 4.9 | 53 | -8.0 | -5.3 | -2.1 | -0.3 | -2.5 | -6.7 | -4.2 | -4.6 | 275 | -7.3 | -5.8 | -2.5 | -1.2 | -0.3 | -2.0 | -6.1 | |
| – | – | – | – | 2.2 | 464 | 1.6 | 3.8 | 2.1 | 2.7 | 2.4 | – | 1.9 | 3.8 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 6.0 | 0.4 | 0.0 | – | 0.0 | 0.0 | -13 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | -2.3 | -2.1 | -2.0 | -2.1 | -2.1 | -2.2 | -2.2 | -2.3 | -8.8 | |
| 6.0 | 0.4 | 230 | 10 | 2.1 | 464 | -11 | 3.8 | 2.1 | 2.7 | 2.3 | 147 | 1.9 | 3.8 | 54 | 81 | 14 | 263 | 16 | 11 | 41 | 98 | 251 | 132 | -3.5 | -1.3 | 379 | |
| -13 | -16 | 207 | 14 | -48 | 424 | -238 | -118 | 223 | -54 | 1.0 | 94 | -77 | -66 | -20 | 4.2 | -95 | 177 | -47 | 167 | -94 | 25 | 133 | 87 | -89 | -108 | 23 | |
| -19 | -17 | -20 | 4.0 | -50 | -40 | -43 | -66 | 73 | -78 | -63 | -53 | -79 | -71 | -74 | -76 | -109 | -86 | -64 | -117 | -134 | -80 | -118 | -47 | -81 | -108 | -354 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.